LENZ Therapeutics Inc (LENZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
LENZ Therapeutics Inc stock (LENZ) is currently trading at $9.03. LENZ Therapeutics Inc PS ratio (Price-to-Sales) is 19.67. Analyst consensus price target for LENZ is $51.29. WallStSmart rates LENZ as Sell.
- LENZ PE ratio analysis and historical PE chart
- LENZ PS ratio (Price-to-Sales) history and trend
- LENZ intrinsic value — DCF, Graham Number, EPV models
- LENZ stock price prediction 2025 2026 2027 2028 2029 2030
- LENZ fair value vs current price
- LENZ insider transactions and insider buying
- Is LENZ undervalued or overvalued?
- LENZ Therapeutics Inc financial analysis — revenue, earnings, cash flow
- LENZ Piotroski F-Score and Altman Z-Score
- LENZ analyst price target and Smart Rating
LENZ Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
LENZ Therapeutics Inc (LENZ) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
LENZ Therapeutics Inc (LENZ) Key Strengths (2)
116.18% of shares held by major funds and institutions
Trading at 1.69x book value, attractively priced
Supporting Valuation Data
LENZ Therapeutics Inc (LENZ) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 19.7x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
LENZ Therapeutics Inc (LENZ) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.69) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (19.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -28.80%, Operating Margin at -151.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -28.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LENZ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LENZ's Price-to-Sales ratio of 19.67x sits near its historical average of 21.84x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 18% below its historical high of 24.12x set in Mar 2026, and 0% above its historical low of 19.67x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~24.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for LENZ Therapeutics Inc (LENZ) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
LENZ Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 18M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 22% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.76, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact LENZ Therapeutics Inc.
Bottom Line
LENZ Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About LENZ Therapeutics Inc(LENZ)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
LENZ Therapeutics Inc is an innovative biopharmaceutical company dedicated to developing breakthrough therapies for neurological disorders, addressing significant unmet medical needs in the central nervous system (CNS). Utilizing advanced research in drug formulation and delivery, LENZ aims to enhance patient outcomes through its proprietary technologies and a robust product pipeline. The company’s strategic partnerships and commitment to rigorous clinical research underscore its potential as a key player in the biopharmaceutical industry, positioning it for considerable growth and influence in the evolving healthcare landscape.